Sept. 8, 2025， InnoCare Pharma announced that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL).
At present, there are still many clinical trials of new anti-cancer technologies in China seeking patients. Consultation on new drugs and technologies, you can contact Beijing South Region Oncology Hospital International Department.
Phone Number：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin’s lymphoma (NHL) that primarily affects middle-aged and elderly patients. The annual incidence of MZL is rising globally. After first-line treatment, patients with R/R MZL lack effective treatment options.
In April 2025, orelabrutinib received approval in China for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). Orelabrutinib has been also approved for the treatment of three other indications in China, including relapsed and refractory (R/R) CLL/SLL, r/r mantle cell lymphoma (R/R MCL) and r/r marginal zone lymphoma (R/R MZL), all of which have been covered in China’s National Reimbursement Drug List.
The Efficacy, Safety, and Rationality of Orelabrutinib Plus Obinutuzumab in Systemic Treatment-Naive Marginal Zone Lymphoma: A Prospective Cohort Study showed that Across the entire study and during induction therapy, the overall response rate (ORR) is 100%. Three patients with partial response (PR) after induction therapy achieved complete response (CR) during maintenance.
The ADCC assays showed orelabrutinib in combination with obinutuzumab regimen induced the most active ADCC response in TMD-8 and REC-1 cell lines.
At present, there are still many clinical trials of new anti-cancer technologies in China seeking patients. Consultation on new drugs and technologies, you can contact Beijing South Region Oncology Hospital International Department.
Phone Number：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Post time: Sep-09-2025